@article{StrengGoettlerHaerleinetal.2019,
  author    = {Streng, Andrea and Goettler, David and Haerlein, Miriam and Lehmann, Lisa and Ulrich, Kristina and Prifert, Christiane and Krempl, Christine and Weißbrich, Benedikt and Liese, Johannes G.},
  title     = {Spread and clinical severity of respiratory syncytial virus A genotype ON1 in Germany, 2011-2017},
  series = {BMC Infectious Diseases},
  volume    = {19},
  journal   = {BMC Infectious Diseases},
  doi       = {10.1186/s12879-019-4266-y},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-201516},
  pages     = {613},
  year      = {2019},
  abstract  = {Background The Respiratory Syncytial Virus (RSV) A genotype ON1, which was first detected in Ontario (Canada) in 2010/11, appeared in Germany in 2011/12. Preliminary observations suggested a higher clinical severity in children infected with this new genotype. We investigated spread and disease severity of RSV-A ON1 in pediatric in- and outpatient settings. Methods During 2010/11 to 2016/17, clinical characteristics and respiratory samples from children with acute respiratory tract infections (RTI) were obtained from ongoing surveillance studies in 33 pediatric practices (PP), one pediatric hospital ward (PW) and 23 pediatric intensive care units (PICU) in Germany. RSV was detected in the respiratory samples by PCR; genotypes were identified by sequencing. Within each setting, clinical severity markers were compared between RSV-A ON1 and RSV-A non-ON1 genotypes. Results A total of 603 children with RSV-RTI were included (132 children in PP, 288 in PW, and 183 in PICU). Of these children, 341 (56.6\%) were infected with RSV-A, 235 (39.0\%) with RSV-B, and one child (0.2\%) with both RSV-A and RSV-B; in 26 (4.3\%) children, the subtype could not be identified. In the 341 RSV-A positive samples, genotype ON1 was detected in 247 (72.4\%), NA1 in 92 (26.9\%), and GA5 in 2 children (0.6\%). RSV-A ON1, rarely observed in 2011/12, was the predominant RSV-A genotype in all settings by 2012/13 and remained predominant until 2016/17. Children in PP or PW infected with RSV-A ON1 did not show a more severe clinical course of disease compared with RSV-A non-ON1 infections. In the PICU group, hospital stay was one day longer (median 8 days, inter-quartile range (IQR) 7-12 vs. 7 days, IQR 5-9; p = 0.02) and duration of oxygen treatment two days longer (median 6 days, IQR 4-9 vs. 4 days, IQR 2-6; p = 0.03) for children infected with RSV-A ON1. Conclusions In children, RSV-A ON1 largely replaced RSV-A non-ON1 genotypes within two seasons and remained the predominant RSV-A genotype in Germany during subsequent seasons. A higher clinical severity of RSV-A ON1 was observed within the group of children receiving PICU treatment, whereas in other settings clinical severity of RSV-A ON1 and non-ON1 genotypes was largely similar.},
  language  = {en}
}
@article{ScheerKremplKallfassetal.2014,
  author    = {Scheer, Sebastian and Krempl, Christine and Kallfass, Carsten and Frey, Stefanie and Jakob, Thilo and Mouahid, Gabriel and Mone, Helene and Schmitt-Graeff, Anette and Staeheli, Peter and Lamers, Marinus C.},
  title     = {S-mansoni Bolsters Anti-Viral Immunity in the Murine Respiratory Tract},
  series = {PLOS ONE},
  volume    = {9},
  journal   = {PLOS ONE},
  number    = {11},
  issn      = {1932-6203},
  doi       = {10.1371/journal.pone.0112469},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-114723},
  pages     = {e112469},
  year      = {2014},
  abstract  = {The human intestinal parasite Schistosoma mansoni causes a chronic disease, schistosomiasis or bilharzia. According to the current literature, the parasite induces vigorous immune responses that are controlled by Th2 helper cells at the expense of Th1 helper cells. The latter cell type is, however, indispensable for anti-viral immune responses. Remarkably, there is no reliable literature among 230 million patients worldwide describing defective anti-viral immune responses in the upper respiratory tract, for instance against influenza A virus or against respiratory syncitial virus (RSV). We therefore re-examined the immune response to a human isolate of S. mansoni and challenged mice in the chronic phase of schistosomiasis with influenza A virus, or with pneumonia virus of mice (PVM), a mouse virus to model RSV infections. We found that mice with chronic schistosomiasis had significant, systemic immune responses induced by Th1, Th2, and Th17 helper cells. High serum levels of TNF-alpha, IFN-gamma, IL-5, IL-13, IL-2, IL-17, and GM-CSF were found after mating and oviposition. The lungs of diseased mice showed low-grade inflammation, with goblet cell hyperplasia and excessive mucus secretion, which was alleviated by treatment with an anti-TNF-alpha agent (Etanercept). Mice with chronic schistosomiasis were to a relative, but significant extent protected from a secondary viral respiratory challenge. The protection correlated with the onset of oviposition and TNF-alpha-mediated goblet cell hyperplasia and mucus secretion, suggesting that these mechanisms are involved in enhanced immune protection to respiratory viruses during chronic murine schistosomiasis. Indeed, also in a model of allergic airway inflammation mice were protected from a viral respiratory challenge with PVM.},
  language  = {en}
}